201 related articles for article (PubMed ID: 22025616)
21. A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).
Mertens HD; Kjaergaard M; Mysling S; Gårdsvoll H; Jørgensen TJ; Svergun DI; Ploug M
J Biol Chem; 2012 Oct; 287(41):34304-15. PubMed ID: 22896701
[TBL] [Abstract][Full Text] [Related]
22. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
23. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
24. Crystal structure of the unoccupied murine urokinase-type plasminogen activator receptor (uPAR) reveals a tightly packed DII-DIII unit.
Liu M; Lin L; Høyer-Hansen G; Ploug M; Li H; Jiang L; Yuan C; Li J; Huang M
FEBS Lett; 2019 Jun; 593(11):1236-1247. PubMed ID: 31044429
[TBL] [Abstract][Full Text] [Related]
25. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.
Høyer-Hansen G; Behrendt N; Ploug M; Danø K; Preissner KT
FEBS Lett; 1997 Dec; 420(1):79-85. PubMed ID: 9450554
[TBL] [Abstract][Full Text] [Related]
26. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
Høyer-Hansen G; Rønne E; Solberg H; Behrendt N; Ploug M; Lund LR; Ellis V; Danø K
J Biol Chem; 1992 Sep; 267(25):18224-9. PubMed ID: 1381366
[TBL] [Abstract][Full Text] [Related]
27. Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.
Rea VE; Lavecchia A; Di Giovanni C; Rossi FW; Gorrasi A; Pesapane A; de Paulis A; Ragno P; Montuori N
Mol Cancer Ther; 2013 Aug; 12(8):1402-16. PubMed ID: 23699658
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
[TBL] [Abstract][Full Text] [Related]
29. Regulation of the uPAR/uPA system expressed on monocytes by the deactivating cytokines, IL-4, IL-10 and IL-13: consequences on cell adhesion to vitronectin and fibrinogen.
Paysant J; Vasse M; Soria J; Lenormand B; Pourtau J; Vannier JP; Soria C
Br J Haematol; 1998 Jan; 100(1):45-51. PubMed ID: 9450789
[TBL] [Abstract][Full Text] [Related]
30. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.
Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M
J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568
[TBL] [Abstract][Full Text] [Related]
31. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy.
Lin L; Gårdsvoll H; Huai Q; Huang M; Ploug M
J Biol Chem; 2010 Apr; 285(14):10982-92. PubMed ID: 20133942
[TBL] [Abstract][Full Text] [Related]
32. Vitronectin binding to urokinase receptor in human breast cancer.
Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.
Czekay RP; Loskutoff DJ
J Cell Physiol; 2009 Sep; 220(3):655-63. PubMed ID: 19472211
[TBL] [Abstract][Full Text] [Related]
34. Intermolecular contact regions in urokinase plasminogen activator receptor.
Liang OD; Bdeir K; Matz RL; Chavakis T; Preissner KT
J Biochem; 2003 Nov; 134(5):661-6. PubMed ID: 14688231
[TBL] [Abstract][Full Text] [Related]
35. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
Chang AW; Kuo A; Barnathan ES; Okada SS
Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
[TBL] [Abstract][Full Text] [Related]
36. Structure and ligand interactions of the urokinase receptor (uPAR).
Kjaergaard M; Hansen LV; Jacobsen B; Gardsvoll H; Ploug M
Front Biosci; 2008 May; 13():5441-61. PubMed ID: 18508598
[TBL] [Abstract][Full Text] [Related]
37. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
[TBL] [Abstract][Full Text] [Related]
38. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
Jo M; Takimoto S; Montel V; Gonias SL
Am J Pathol; 2009 Jul; 175(1):190-200. PubMed ID: 19497996
[TBL] [Abstract][Full Text] [Related]
39. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
Tarui T; Andronicos N; Czekay RP; Mazar AP; Bdeir K; Parry GC; Kuo A; Loskutoff DJ; Cines DB; Takada Y
J Biol Chem; 2003 Aug; 278(32):29863-72. PubMed ID: 12754207
[TBL] [Abstract][Full Text] [Related]
40. Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.
De Lorenzi V; Sarra Ferraris GM; Madsen JB; Lupia M; Andreasen PA; Sidenius N
EMBO Rep; 2016 Jul; 17(7):982-98. PubMed ID: 27189837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
